Pacific Biosciences of California reported a quarterly loss of $0.12 per share, beating the Zacks Consensus Estimate for a $0.17 loss by $0.05 per share. The result also improved from a $0.15 loss per share a year ago, indicating modest earnings progress. The update is favorable for PACB, though the impact is likely limited to the individual stock.
Pacific Biosciences of California reported a quarterly loss of $0.12 per share, beating the Zacks Consensus Estimate for a $0.17 loss by $0.05 per share. The result also improved from a $0.15 loss per share a year ago, indicating modest earnings progress. The update is favorable for PACB, though the impact is likely limited to the individual stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
